Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6526
    +0.0026 (+0.40%)
     

  • OIL

    83.14
    +0.33 (+0.40%)
     

  • GOLD

    2,340.70
    +2.30 (+0.10%)
     

  • Bitcoin AUD

    98,187.16
    -4,213.83 (-4.12%)
     

  • CMC Crypto 200

    1,332.29
    -50.28 (-3.64%)
     

  • AUD/EUR

    0.6084
    +0.0013 (+0.22%)
     

  • AUD/NZD

    1.0948
    +0.0006 (+0.06%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,074.08
    +33.70 (+0.42%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,002.99
    -85.71 (-0.47%)
     

  • Hang Seng

    17,269.04
    +67.77 (+0.39%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Venclexta: A Solid Growth Driver for AbbVie in Future Years

Margaret Patrick
Updated
Venclexta: A Solid Growth Driver for AbbVie in Future Years

AbbVie (ABBV) reported global Venclexta sales worth $96 million in the third quarter, a YoY (year-over-year) rise of more than 100% on both an operational and a reported basis. As per the company’s third-quarter earnings conference call, this performance was mainly attributable to the FDA’s approval of the drug in a broader R/R (relapsed/refractory) CLL (chronic lymphocytic leukemia) indication. The company reported Venclexta sales worth $69 million in the US market, a YoY rise of more than 100%.

Continue reading